



Kinase Inhibitors in Cancer and Central Nervous System

Guest Editor:

Prof. Dr. Thierry Besson

Normandie Univ, UNIROUEN,
INSA Rouen, CNRS, COBRA UMR
6014, F-76000 Rouen, France

thierry.besson@univ-rouen.fr

Deadline for manuscript
submissions:

closed (30 November 2019)

Message from the Guest Editor

Protein kinases catalyse protein phosphorylation—a key cellular regulatory mechanism which is frequently dysregulated in human diseases. Kinases have consequently been linked to the progress of a variety of diseases, including cancer and neurodegenerative disorders. Therefore, the search for therapeutic inhibitors of specific kinases has been developed in the last three decades as a major approach to discovering new therapeutic drugs. Initially focused on the discovery, optimization, and characterization of tyrosine kinase inhibitors and on cancer indications, the field is now rapidly expanding towards serine/threonine kinases and essentially all other therapeutic indications as neurodegenerative diseases (Alzheimer's disease, Down syndrome).

In this Special Issue, our goal is to highlight papers describing an intended inhibition of specific kinases, although they are not always the initial and main target of the compounds tested. In silico molecular design connected with the development of chemical syntheses and pertinent comments on the forthcoming applications of these inhibitors will be particularly appreciated.

